ArticleFrontiers in immunology2012
Mesenchymal stem cell-derived hepatocytes for functional liver replacement.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Chaperone-assisted E3 ligase-engineered mesenchymal stem cells target hyperglycemia-induced p53 for ubiquitination and proteasomal degradation ameliorates self-renewal.Biological research · 2025Article
- Constructing biomimetic liver models through biomaterials and vasculature engineering.Regenerative biomaterials · 2022Review
- Glutathione-related inflammatory signature in hepatocytes differentiated from the progenitor mesenchymal stem cells.Heliyon · 2020Article
- Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?Frontiers in immunology · 2020Review
- Bone Marrow-Derived Mesenchymal Stem Cell Potential Regression of Dysplasia Associating Experimental Liver Fibrosis in Albino Rats.BioMed research international · 2019Article
- Urine-derived cells for human cell therapy.Stem cell research & therapy · 2018Review
- Human CD34(lo)CD133(lo) fetal liver cells support the expansion of human CD34(hi)CD133(hi) hematopoietic stem cells.Cellular & molecular immunology · 2016Article
- Mesenchymal stem cells in the treatment of type 1 diabetes mellitus.Endocrine pathology · 2015Review
- Tumor necrosis factor-inducible gene 6 promotes liver regeneration in mice with acute liver injury.Stem cell research & therapy · 2015Article
- Expression and clinical significance of colorectal cancer stem cell marker EpCAMOncology letters · 2014Article
- Article
- Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.Biotechnology and bioengineering · 2014Article
- Mesenchymal stem cells: are we ready for clinical application in transplantation and tissue regeneration?Frontiers in immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells represent an alternate cell source to substitute for primary hepatocytes in hepatocyte transplantation because of their multiple differentiation potential and nearly unlimited availability. They may differentiate into hepatocyte-like cells in vitro and maintain specific hepatocyte functions also after transplantation into the regenerating livers of mice or rats both under injury and non-injury conditions. Depending on the underlying liver disease their mode of action is either to replace the diseased liver tissue or to support liver regeneration through their anti-inflammatory and anti-apoptotic as well as their pro-proliferative action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.